...A. In the third quarter, we continued to deliver double-digit revenue growth, important successes in pricing and reimbursement and continued progress of the pipeline. B. Product and royalty revenues were $914 million in the quarter with an 11% growth year-over-year, driven by Jakafi and Opzelura. C. Jakafi net sales in the quarter were impacted by inventory variation, which Christiana will detail in her prepared remarks. D. As you see in the first 9 months, Jakafi growth continues at a rate of around 8% this year. E. The growth trajectory of Opzelura continued in the third quarter with net product revenue of $92 million driven by both new patients and refills in AD and Vitiligo. F. In the first 9 months of 2023, Opzelura revenues contributed $229 million, and we expect Opzelura to continue to be a key contributor to the growth of Incyte in the next years. G. First, as the IRA is implemented, we secured small biotech exception status for ruxolitinib. H. This has 2 impacts on Jakafi pricing...
